|
PROXIMAGEN NEUROSCIENCE PLC
(Proximagen or the Company)
BUSINESS INITIATIVE OF THE YEAR AWARD
London, UK, 24 November 2005 - Proximagen Neuroscience plc (AIM: PRX), the specialty drug discovery and development company focused on neurodegenerative diseases, is pleased to announce that it has been awarded the "Business Initiative Of The Year" award at yesterday's Times Higher Awards Ceremony 2005.
Proximagen was praised for the strength, focus and drive of its management team, for generating profits and for floating on the London Stock Exchange's Alternative Investment Market little more than a year after it was created in November 2003.
The event received widespread support and included a special video message for the ceremony from Prime Minister Tony Blair, in which he hailed the achievements of the UK's world-beating higher education institutions.
Prizes were presented by a number of distinguished guests including Bill Rammell, Minister for Higher Education, and Colin Blakemore, Chief Executive of the Medical Research Council.
Kenneth Mulvany, Chief Executive Officer of Proximagen, who collected the award with the Company's Chief Scientific Officer, Professor Peter Jenner, said: We are absolutely delighted to have won this award. Proximagen is a great example of the partnership that can be created between universities and the commercial world. The rapid growth and success of Proximagen reflects the entrepreneurial spirit developed at King's College London by KCL Enterprises in conjunction with the university IP commercialision group IP2IPO.
Richard Lomer, regional sales manager of InFocus, sponsor of the award, said: It is important to acknowledge great vision and dedication, not just to a business idea but to improving people's lives. Proximagen has grown from small beginnings to great results. Professor Peter Jenner and his team richly deserve this recognition from their peers.
For more information please contact:
Proximagen Neuroscience plc (www.proximagen.com)
020 7848 6011
Kenneth Mulvany, Chief Executive Officer
James Hunter, Financial Controller
Buchanan Communications
020 7466 5000
Tim Anderson / Mark Court / Mary-Jane Johnson
About Proximagen
Proximagen is a drug discovery and development company that is primarily focused on the identification and subsequent out-licensing of novel therapeutics to improve the quality of life for patients suffering from neurodegenerative disease such as Parkinson's disease and Alzheimer's disease.
The Company was founded by Professor Peter Jenner in conjunction with King's College in November 2003 to draw upon over 25 years of pre-eminent neurodegenerative research.
Proximagen joined the AIM market of the London Stock Exchange in March 2005.
This information is provided by RNS
The company news service from the London Stock Exchange
| 
